Nurix Therapeutics, Inc.
NRIX
$10.55
$0.313.03%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -208.40M | -193.57M | -176.98M | -165.00M | -144.73M |
| Total Depreciation and Amortization | 15.37M | 15.13M | 14.48M | 13.72M | 12.96M |
| Total Amortization of Deferred Charges | 1.30M | 1.30M | 1.40M | 1.40M | 1.40M |
| Total Other Non-Cash Items | 22.23M | 22.96M | 23.98M | 25.89M | 26.98M |
| Change in Net Operating Assets | -22.22M | -18.40M | 39.97M | 27.89M | 28.53M |
| Cash from Operations | -191.72M | -172.58M | -97.14M | -96.10M | -74.86M |
| Capital Expenditure | -9.87M | -9.27M | -9.75M | -9.87M | -9.01M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -257.82M | -248.44M | -121.52M | -77.29M | 96.75M |
| Cash from Investing | -267.69M | -257.71M | -131.27M | -87.16M | 87.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 485.53M | 485.68M | 285.17M | 241.10M | 3.36M |
| Repurchase of Common Stock | -15.00K | -15.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -15.00K | -15.00K | -- |
| Cash from Financing | 485.52M | 485.67M | 285.15M | 241.09M | 3.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.10M | 55.37M | 56.74M | 57.83M | 16.24M |